Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Tran

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Nature Biomedical Engineering|April 2, 2019
Biodegradable and flexible arterial-pulse sensor for the wireless monitoring of blood flowClementine M Boutry, Levent Beker, Yukitoshi Kaizawa, et al.
American Journal of Clinical Dermatology|June 18, 2026
Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology|September 15, 2025
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology|January 23, 2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology|May 24, 2024
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
Burns : Journal of the International Society for Burn Injuries|February 18, 2026
Analysis of treatment pathways and long-term prevalence of pruritus after burn - An observational study with real-world dataJulia Kleinhapl, Lucineia Gainski Danielski, John Nabei Ekale, et al.
Journal of the American Academy of Dermatology|October 18, 2024
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trialMelissa Piliang, Charles Lynde, Brett King, et al.
Dermatology and Therapy|March 25, 2026
Validation of Self-Reported Vitiligo Prevalence among Adults in the USA and Europe Using the 2024 National Health and Wellness SurveySeemal R Desai, Khaled Ezzedine, Markus Böhm, et al.
Cerebral Cortex (New York, N.Y. : 1991)|October 24, 2006
Mapping cortical thickness in children with 22q11.2 deletionsCarrie E Bearden, Theo G M van Erp, Rebecca A Dutton, et al.
American Journal of Medical Genetics. Part A|July 2, 2003
Relation between apolipoprotein E genotype, hepatitis B virus status, and thyroid status in a sample of older persons with Down syndromeMaire E Percy, Zoya Potyomkina, Arthur J Dalton, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Nature Biomedical Engineering|April 2, 2019
Biodegradable and flexible arterial-pulse sensor for the wireless monitoring of blood flowClementine M Boutry, Levent Beker, Yukitoshi Kaizawa, et al.
American Journal of Clinical Dermatology|June 18, 2026
Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology|September 15, 2025
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology|January 23, 2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology|May 24, 2024
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
Burns : Journal of the International Society for Burn Injuries|February 18, 2026
Analysis of treatment pathways and long-term prevalence of pruritus after burn - An observational study with real-world dataJulia Kleinhapl, Lucineia Gainski Danielski, John Nabei Ekale, et al.
Journal of the American Academy of Dermatology|October 18, 2024
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trialMelissa Piliang, Charles Lynde, Brett King, et al.
Dermatology and Therapy|March 25, 2026
Validation of Self-Reported Vitiligo Prevalence among Adults in the USA and Europe Using the 2024 National Health and Wellness SurveySeemal R Desai, Khaled Ezzedine, Markus Böhm, et al.
Cerebral Cortex (New York, N.Y. : 1991)|October 24, 2006
Mapping cortical thickness in children with 22q11.2 deletionsCarrie E Bearden, Theo G M van Erp, Rebecca A Dutton, et al.
American Journal of Medical Genetics. Part A|July 2, 2003
Relation between apolipoprotein E genotype, hepatitis B virus status, and thyroid status in a sample of older persons with Down syndromeMaire E Percy, Zoya Potyomkina, Arthur J Dalton, et al.
Pageof 8